Yashiro M, Matsuoka T. Fibroblast growth factor receptor signaling as therapeutic targets in gastric cancer. World J Gastroenterol 2016; 22(8): 2415-2423 [PMID: 26937130 DOI: 10.3748/wjg.v22.i8.2415]
Corresponding Author of This Article
Masakazu Yashiro, MD, Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan. m9312510@med.osaka-cu.ac.jp
Research Domain of This Article
Oncology
Article-Type of This Article
Topic Highlight
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Feb 28, 2016; 22(8): 2415-2423 Published online Feb 28, 2016. doi: 10.3748/wjg.v22.i8.2415
Fibroblast growth factor receptor signaling as therapeutic targets in gastric cancer
Masakazu Yashiro, Tasuku Matsuoka
Masakazu Yashiro, Tasuku Matsuoka, Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan
Masakazu Yashiro, Oncology Institute of Geriatrics and Medical Science, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan
Author contributions: Yashiro M and Matsuoka T designed this review; Yashiro M wrote and edited the manuscript.
Supported by KAKENHI (partially, Grant-in-Aid for Scientific Research, No. 23390329).
Conflict-of-interest statement: There are not any financial or other interests with regard to the submitted manuscript that might be construed as a conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Masakazu Yashiro, MD, Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan. m9312510@med.osaka-cu.ac.jp
Telephone: +81-6-66453838 Fax: +81-6-66466450
Received: April 27, 2015 Peer-review started: May 1, 2015 First decision: May 18, 2015 Revised: May 25, 2015 Accepted: December 8, 2015 Article in press: December 8, 2015 Published online: February 28, 2016
Abstract
Fibroblast growth factor receptors (FGFRs) regulate a variety of cellular functions, from embryogenesis to adult tissue homeostasis. FGFR signaling also plays significant roles in the proliferation, invasion, and survival of several types of tumor cells. FGFR-induced alterations, including gene amplification, chromosomal translocation, and mutations, have been shown to be associated with the tumor initiation and progression of gastric cancer, especially in diffuse-type cancers. Therefore, the FGFR signaling pathway might be one of the therapeutic targets in gastric cancer. This review aims to provide an overview of the role of FGFR signaling in tumorigenesis, tumor progression, proliferation, and chemoresistance. We also discuss the accumulating evidence that demonstrates the effectiveness of using clinical therapeutic agents to inhibit FGFR signaling for the treatment of gastric cancer.
Core tip: Fibroblast growth factor receptor (FGFR) is one of the drivers signaling in the development of gastric cancer. The use of molecular agents as targets of the FGFRs pathway has currently been approved in experimental and clinical trials as a mono-targeted approach or in combination with chemotherapeutic agents. FGFRs might be a promising therapeutic target for the treatment of gastric cancer.
